AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.

Community Guidelines: bit.ly/2MgAcio

ADC Therapeutics

Viela Bio

Cellular Biomedicine Group

Moderna

FibroGen

Innate Pharma

Nektar Therapeutics

PhaseBio Pharmaceuticals

Rani Therapeutics

AstraZeneca

Join us live at the London Stock Exchange’s Market Open Ceremony with our CEO Pascal Soriot and our leadership team as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science.

We are pleased to report 2023 was another year of double-digit growth and scientific progress, with investments in exciting areas of science that lay the foundations for continued long-term success. 

This year we are excited to celebrate our 25th anniversary with our teams around the world. Thank you for unlocking the power of what science can do for people, society and the planet. 

#AZN #WhatScienceCanDo

Our Full Year and Q4 2023 Results announcement will be available from 07:00 GMT on Thursday 8 February 2024. 
 
Join the accompanying webcast for investors and analysts at 11:45 GMT – you can register to attend here: https://lnkd.in/eBerW6Vc

Join us live tomorrow at the London Stock Exchange’s Market Open Ceremony as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science. 

Set up a reminder to watch here: https://learn.az/6042V3qhg

Innovations in cell therapy are advancing the treatment of some blood cancers for patients. However, there are challenges in using the therapy to treat other types of cancer.  

Susan Galbraith, EVP of Oncology R&D, shares her thoughts on how we can expand the potential of cell therapies to reach more people impacted by cancer. https://learn.az/6049psAnh 

World Economic Forum 
#WorldCancerDay #CloseTheCareGap

Congratulations to Prof Sir Mene Pangalos, who has received the prestigious BioIndustry Association (BIA) Lifetime Achievement Award. The award celebrates not only Mene’s career, but recognises the incredible impact scientists have on patients and society. Learn more: https://learn.az/6047T0fpJ 

#WhatScienceCanDo

Providing young people access to quality science, technology, engineering and mathematics (#STEM) education can inspire them to pursue their interests and explore potential careers in STEM.

Our global programmes, supported by our four key pillars, foster inclusive environments dedicated to inspiring the next generation of scientists, researchers and innovators. 

Learn more: https://learn.az/6049T5GW1

We’re taking action to protect and restore ecosystems by lowering the environmental footprint of healthcare whilst investing in nature and biodiversity. 

As part of our commitment to following the science and to transparently communicating our progress on how we are protecting biodiversity, this week, we became an Early Adopter of the Taskforce on Nature-related Financial Disclosures (TNFD). 

TNFD will support us in identifying and assessing our nature-related dependencies, impacts, risks, and opportunities.

Discover more here: https://learn.az/6047rtPlt

#TNFDEarlyAdopter #TNFD #WEF24

Health must be front and centre of tackling the climate crisis. By taking a health-centred approach, we can improve both the sustainability and resilience of our health systems. 

We co-hosted a discussion on this critical topic with Vanessa Kerry, MD MSc from the World Health Organization and Seed Global Health, and Devex on the practical steps needed to strengthen financing of health systems in the face of climate change.

Expanding the resources necessary to drive transformative action is urgent for the health of people, society and our planet. #ItStartsWithHealth #WEF24

We’re proud to have launched a renewable power agreement in China together with Lonza, Novartis, Novo Nordisk, Roche and Envision Energy. 

Convened through the The Sustainable Markets Initiative Health Systems Task Force, this milestone agreement is the first time the pharmaceuticals sector has collaborated on green power in China, and it’s set to achieve annual CO2e savings of around 120,000 tonnes. That’s the equivalent of taking 25,000 cars off the road.
 
We can achieve more when we work in partnership. 
 
Learn more: https://lnkd.in/eTVhjeqe

XETRA:ZEG

AstraZeneca plc

Last Close

12,060.00

26/07 15:49

Market Cap

1.88B

Beta: 0.17

Volume Today

1.50M

Avg: 7.56K

PE Ratio

34.26

PFCF: 28.97

Dividend Yield

1.80%

Payout:75.97%